DocGo Inc. (NASDAQ:DCGO) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to US$0.59 in the week after its latest quarterly results. The results don't look great, especially considering that statutory losses grew 22% toUS$0.15 per share. Revenues of US$76m did beat expectations by 4.3%, but it looks like a bit of a cold comfort. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Taking into account the latest results, DocGo's five analysts currently expect revenues in 2026 to be US$306.3m, approximately in line with the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 82% to US$0.34. Before this earnings announcement, the analysts had been modelling revenues of US$298.9m and losses of US$0.32 per share in 2026. So it's pretty clear consensus is mixed on DocGo after the new consensus numbers; while the analysts lifted revenue numbers, they also administered a moderate increase in per-share loss expectations.

Spiting the revenue upgrading, the average price target fell 11% to US$1.87, clearly signalling that higher forecast losses are a valuation concern. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on DocGo, with the most bullish analyst valuing it at US$3.00 and the most bearish at US$1.00 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting DocGo is an easy business to forecast or the the analysts are all using similar assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that DocGo's revenue growth is expected to slow, with the forecast 2.0% annualised growth rate until the end of 2026 being well below the historical 11% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 4.7% annually. Factoring in the forecast slowdown in growth, it seems obvious that DocGo is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple DocGo analysts - going out to 2027, and you can see them free on our platform here.

You still need to take note of risks, for example - DocGo has 3 warning signs we think you should be aware of.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.